ArticlemSphere2019
The Glucoamylase Inhibitor Acarbose Has a Diet-Dependent and Reversible Effect on the Murine Gut Microbiome.
Article in mSphere, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 93 citations in OpenAlex.
- Effects of Non-insulin Anti-hyperglycemic Agents on Gut Microbiota: A Systematic Review on Human and Animal Studies.Frontiers in endocrinology · 2020Pooled it
- Effect of acarbose and vildagliptin on plasma trimethylamine N-oxide levels in patients with type 2 diabetes mellitus: a 6-month, two-arm randomized controlled trial.Frontiers in endocrinology · 2025Trial
- Longitudinal associations of dietary fiber and its source with 48-week weight loss maintenance, cardiometabolic risk factors and glycemic status under metformin or acarbose treatment: a secondary analysis of the March randomized trial.Nutrition & diabetes · 2024Trial
- Habitual Dietary Intake Affects the Altered Pattern of Gut Microbiome by Acarbose in Patients with Type 2 Diabetes.Nutrients · 2021Trial
- Lachnospiraceae in the Food-Gut Axis: A Critical Review of Dietary Modulation, Immune Regulation, and Translational Barriers.Comprehensive reviews in food science and food safety · 2026Review
- Acarbose redirects gut microbiome utilization of dietary carbohydrates to suppress anaphylaxis in mice.Nature microbiology · 2026Article
- Cardiac function of colorectal cancer mice is remotely controlled by gut microbiota: regulating serum metabolites and myocardial cytokines.Animal microbiome · 2025Article
- Systems genetics uncovers associations among host amylase locus, gut microbiome, and metabolic traits in mice.Microbiome · 2025Article
- Acarbose impairs gutmBio · 2024Article
- Natural Foraging Selection and Gut Microecology of Two Subterranean Rodents from the Eurasian Steppe in China.Animals : an open access journal from MDPI · 2024Article
- Two weeks of acarbose treatment shows no effect on gut microbiome composition in patients with type 2 diabetes: a randomised, placebo-controlled, double-blind, crossover study.Endocrine connections · 2024Article
- Acarbose Impairs GutbioRxiv : the preprint server for biology · 2024Article
- Presence of digestible starch impactsFood & function · 2024Article
- Inactivation of the antidiabetic drug acarbose by human intestinal microbial-mediated degradation.Nature metabolism · 2023Article
- Characterizing the Effect of Amylase Inhibitors on Maltodextrin Metabolism by Gut Bacteria Using Fluorescent Glycan Labeling.ACS chemical biology · 2023Article
- The Role of Intestinal Flora and Its Metabolites in Heart Failure.Infection and drug resistance · 2023Review
- Application of natural compounds in the treatment and prevention of prediabetes.Frontiers in nutrition · 2023Review
- Exploring the role of gut microbiota in advancing personalized medicine.Frontiers in microbiology · 2023Review
- α-Glucosidase inhibitors boost gut immunity by inducing IgA responses in Peyer's patches.Frontiers in immunology · 2023Article
- Mechanisms of gut microbiota-immune-host interaction on glucose regulation in type 2 diabetes.Frontiers in microbiology · 2023Review
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Acarbose is a safe and effective medication for type 2 diabetes that inhibits host glucoamylases to prevent starch digestion in the small intestines and thus decrease postprandial blood glucose levels. This results in an increase in dietary starch in the distal intestine, where it becomes food for the gut bacterial community. Here, we examined the effect of acarbose therapy on the gut community structure in mice fed either a high-starch (HS) or high-fiber diet rich in plant polysaccharides (PP). The fecal microbiota of animals consuming a low dose of acarbose (25 ppm) was not significantly different from that of control animals that did not receive acarbose. However, a high dose of acarbose (400 ppm) with the HS diet resulted in a substantial change to the microbiota structure. Most notably, the HS diet with a high dose of acarbose lead to an expansion of the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.